Questionable value of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound - Top-Institutions - MDSpire

Questionable value of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound

  • By

  • Christina Lenschow

  • Andreas Wennmann

  • Anne Hendricks

  • Christoph-Thomas Germer

  • Martin Fassnacht

  • Andreas Buck

  • Rudolf A. Werner

  • Lars Plassmeier

  • Nicolas Schlegel

  • August 9, 2022

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrine Surgery
    • Nuclear Medicine
    • Endocrinology

  • #2

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Endocrine Surgery
    • Nuclear Medicine
    • Endocrinology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrine Surgery
    • Nuclear Medicine
    • Endocrinology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Endocrine Surgery
    • Nuclear Medicine
    • Endocrinology

  • #5

    University of Michigan Health System
    University of Michigan Health System

    Ann Arbor, MI

    Key Differentiators

    • Endocrine Surgery
    • Nuclear Medicine
    • Endocrinology

Original Source(s)

Questionable value of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound

  • by Christina Lenschow, Andreas Wennmann, Anne Hendricks, Christoph-Thomas Germer, Martin Fassnacht, Andreas Buck, Rudolf A. Werner, Lars Plassmeier, Nicolas Schlegel

  • August 9, 2022

Related Content

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Enduring Surgical Approach: The Systemic-to-Pulmonary Artery Shunt in Congenital Heart Defect Management